Y-mAbs Therapeutics (YMAB) Misses Q3 EPS by 6c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q3 EPS of ($0.66), $0.06 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $9 million versus the consensus estimate of $10.87 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Morgan Stanley upgrades CDW on stronger AI-driven server demand